Biogen (BIIB) said Tuesday that it has initiated dosing in the phase 3 Transcend study of felzartamab to treat adult kidney transplant recipients diagnosed with late antibody-mediated rejection, or late AMR.
The biotech company said the study, which will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo, will enroll approximately 120 kidney transplant recipients with late AMR.
The primary endpoint of study is the percentage of participants who achieve resolution by biopsy of AMR at 6 months.
Price: 149.33, Change: -1.38, Percent Change: -0.92
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。